$311 Million is the total value of Krensavage Asset Management, LLC's 13 reported holdings in Q1 2020. The portfolio turnover from Q4 2019 to Q1 2020 was 8.3% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| UTHR | Buy | UNITED THERAPEUTICS CORP | $51,172,000 | +26.0% | 539,646 | +17.1% | 16.46% | +18.8% |
| REGN | Sell | REGENERON PHARMACEUTICALS | $42,392,000 | +8.1% | 86,817 | -16.9% | 13.64% | +1.9% |
| ALXN | Buy | ALEXION PHARMACEUTICALS INC | $41,495,000 | +22.4% | 462,138 | +47.4% | 13.35% | +15.3% |
| ENTA | Buy | ENANTA PHARMACEUTICALS INC | $36,017,000 | +19.1% | 700,318 | +43.1% | 11.58% | +12.3% |
| BIIB | Buy | BIOGEN INC | $35,046,000 | +7.5% | 110,771 | +0.8% | 11.27% | +1.3% |
| TARO | Buy | TARO PHARMACEUTICAL INDUS | $29,821,000 | -0.2% | 487,275 | +43.4% | 9.59% | -5.9% |
| MCK | Sell | MCKESSON CORP | $29,528,000 | -16.1% | 218,306 | -14.2% | 9.50% | -20.9% |
| ALKS | Buy | ALKERMES PLC | $16,837,000 | -8.8% | 1,167,631 | +29.0% | 5.42% | -14.0% |
| GILD | Sell | GILEAD SCIENCES INC | $8,803,000 | +11.2% | 117,755 | -3.4% | 2.83% | +4.8% |
| RTIX | Buy | RTI SURGICAL HDS INC | $6,887,000 | -30.7% | 4,027,772 | +11.0% | 2.22% | -34.7% |
| IVC | Buy | INVACARE CORP | $6,592,000 | -17.0% | 887,246 | +0.8% | 2.12% | -21.8% |
| ANAB | Buy | ANAPTYSBIO INC | $6,272,000 | -12.4% | 443,877 | +0.8% | 2.02% | -17.4% |
| CHNG | New | CHANGE HEALTHCARE INC | $36,000 | – | 3,639 | +100.0% | 0.01% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2020-05-18
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| UNITED THERAPEUTICS CORP | 36 | Q3 2023 | 18.1% |
| Enanta Pharmceuticals Inc | 35 | Q3 2023 | 16.7% |
| INVACARE CORP | 28 | Q3 2021 | 5.8% |
| RTI SURGICAL INC | 23 | Q2 2020 | 7.9% |
| MCKESSON CORP | 20 | Q3 2022 | 16.3% |
| BIOGEN INC | 19 | Q3 2023 | 16.0% |
| MERCK & CO. INC. | 18 | Q1 2019 | 11.1% |
| DIGIRAD CORP | 18 | Q1 2019 | 1.0% |
| REGENERON PHARMACEUTICALS | 16 | Q3 2023 | 16.1% |
| ALKERMES PLC | 16 | Q3 2023 | 14.1% |
View Krensavage Asset Management, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| SURGALIGN HOLDINGS, INC. | February 19, 2021 | 5,380,449 | 6.6% |
| RTI SURGICAL, INC. | February 14, 2019 | 3,852,567 | 6.1% |
| Aviragen Therapeutics, Inc. | February 15, 2018 | 2,292,058 | 5.9% |
| ENANTA PHARMACEUTICALS INC | February 15, 2017 | 883,902 | 4.6% |
| Biota Pharmaceuticals, Inc. | February 17, 2016 | 2,267,655 | 5.9% |
View Krensavage Asset Management, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SCHEDULE 13G | 2024-02-27 |
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-15 |
| 13F-HR | 2023-08-11 |
| 13F-HR | 2023-05-16 |
| 13F-HR | 2023-02-15 |
| 13F-HR | 2022-11-15 |
| 13F-HR | 2022-08-16 |
| 13F-HR | 2022-05-17 |
| 13F-HR | 2022-02-15 |
View Krensavage Asset Management, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.